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Introduction: Malignant pleural mesothelioma was once a rare finding but its incidence is increasing worldwide,
most likely because of widespread exposure to asbestos. Although complete surgical resection is considered the
only curative treatment, the results of surgery have shown a median survival time of only one year. In inoperable
cases, chemotherapy, radiotherapy, and a combination of both have been considered as palliative therapy.
Therefore, outcomes for inoperable cases have been poor. Here, we report the case of a long-term survivor treated
with hyperthermia and chemotherapy.
Case presentation: A 61-year-old Japanese man with a performance status of 1 due to chest pain was referred to
our hospital. He had a history of asbestos exposure for approximately five years. A computed tomography scan
showed diffuse extensive right pleural thickening with small nodular lesions, and video-assisted thoracoscopy
revealed tumor invasion of the ipsilateral chest wall muscles. The histopathologic findings were consistent with a
diagnosis of malignant pleural mesothelioma (sarcomatoid type). The tumor was diagnosed as being stage
cT3N0M0. Our patient refused any invasive therapies including surgery and radiotherapy, and was therefore treated
with hyperthermia and systemic chemotherapy with agents such as cisplatin and irinotecan. He underwent three
hyperthermia sessions and a single course of chemotherapy without any severe complications. One month after
treatment, a follow-up computed tomography scan showed no definitive abnormality in the thoracic space. Our
patient has subsequently survived without any evident disease for more than seven years.
Conclusions: The combination of hyperthermia and chemotherapy may be a novel and safe therapeutic option for
malignant pleural mesothelioma, and can be considered for patients ineligible for radical treatment. Further clinical
studies of the combination of hyperthermia and chemotherapy are needed to confirm the effects of this treatment
on malignant pleural mesothelioma.
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Malignant pleural mesothelioma (MPM) was once a rare
finding, but its incidence is increasing worldwide, most
likely because of widespread exposure to asbestos [1,2].
MPM is considered to have a poor prognosis, and
complete surgical resection is the only curative treatment.
However, the post-operative median survival time (MST)* Correspondence: noriyukiokonogi@gmail.com
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reproduction in any medium, provided the orafter surgery is only approximately one year [3-5]. More-
over, there is no standard treatment for inoperable MPM.
We report a case of a seven-year disease-free survivor
who was diagnosed as having MPM and was treated with
hyperthermia and chemotherapy.
Case presentation
A 61-year-old Japanese man with a performance status of
1 due to chest pain was referred to our hospital. He
reported a persistent fever for approximately one month.
The results of a computed tomography (CT) scan revealedl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Computed tomography images before treatment.
A chest computed tomography scan before treatment shows right
pleural diffuse thickening (arrows).
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lar lesions (Figure 1). Our patient was a social drinker with
a smoking history of 40 pack-years as well as a history of
asbestos exposure for approximately five years.
To confirm the diagnosis of MPM, a video-assisted thor-
acoscopic lung biopsy was performed, which revealed
tumor invasion of the ipsilateral chest wall muscles. Al-
though the tumor markers for malignant mesothelioma,
such as cytokeratin fragment (CYFRA) and tissue poly-
peptide antigen (TPA), were within normal limits, the hya-
luronic acid concentration in the right pleural effusion
was 55,000ng/mL, which was suggestive of MPM [3].
Hematoxylin and eosin staining of the specimen revealed
disarrayed proliferation of large, spindle-shaped tumorFigure 2 Pathological findings. (A) Disarrayed proliferation of large, spind
and eosin staining. (B) Positive staining of cells for calretinin.cells with fibrous stroma (Figure 2). Immunohistochemis-
try testing was positive for epithelial membrane antigen,
calretinin, vimentin, and cytokeratin 5/6. In contrast,
staining results for carcinoembryonic antigen (CEA),
tissue-specific transcription factor 1 (TTF-1), S-100,
and CD34 were negative. These histopathologic findings
were consistent with the diagnosis of MPM (sarcoma-
toid type). On the basis of these clinical examinations,
the tumor was diagnosed as being T3N0M0 stage III
MPM according to the Union for International Cancer
Control guidelines.
Our patient was eligible for surgery; however, he
refused any invasive therapies such as surgery and radio-
therapy. Therefore, we proposed systemic chemotherapy
with hyperthermia, which was used by our institution at
that time for unresectable lung cancers with or without
malignant pleural effusion [4,5]. Our patient agreed to
this treatment strategy; he provided his written informed
consent after a comprehensive discussion regarding the na-
ture of his illness and standard therapeutic options,
including surgery and combined modality therapy. Three
weeks after the biopsy, systemic chemotherapy with hyper-
thermia was administered once a week. The chemotherapy
regimen included cisplatin 60mg/m2 (100mg/body) on
day one and irinotecan 60mg/m2 (100mg/body) on
days one, eight, and 15. Hyperthermia was performed
using a radiofrequency (RF)-capacitive heating appar-
atus (Thermotron-RF 8; Yamamoto Vinita Co. Ltd.,
Osaka, Japan) once a week (on days one, eight, and 15) for
approximately 60 minutes immediately after irinotecan
administration. The electrodes measured 30cm in diam-
eter and were placed in front of and behind our patient to
heat the entire thoracic cavity. A pair of overlay boluses
were used to prevent any edge effect and for cooling thele-shaped tumor cells in fibrous stroma was revealed by hematoxylin
Figure 3 A computed tomography image at the time of
complete response. One month after the treatment completion,
the pleural thickening had completely disappeared. A small amount
of right pleural effusion was observed, but has not increased since.
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nodular lesions were approximately 42.5°C and the right
pleural thickening >40°C.
Shortly before initiating the second chemotherapy
course, a month after the first treatment cycle, a CT scan
revealed that the pleural thickening had disappeared
(Figure 3). The right pleural effusion was drained only once
during biopsy, and pleural effusion had not increased
thereafter. Consequently, our patient underwent three ses-
sions of hyperthermia and a single course of chemotherapy
without any severe complications. He was subsequently
followed-up by CT scan and 18F-fluorodeoxy-glucose-
positron emission tomography (18FDG-PET), performed
six years after the end of treatment; the results revealed no
evidence of recurrence or metastasis (Figure 4). Our
patient has been disease free for more than seven years
without any complications.Figure 4 Computed tomography and positron emission tomography-
computed tomography scan (A) and a positron emission tomography scan
treatment. The diffuse pleural thickening has disappeared. There is no evidDiscussion
MPM develops after asbestos exposure and has a long
latency period. Its incidence is currently increasing
worldwide because of the extent of asbestos exposure
between the years 1965 and 1980 [1,2]. MPM has a poor
prognosis, mainly because of its inherent resistance to
conventional treatment. Therefore, it is necessary to
identify novel treatment strategies.
Radical surgical resection is considered the only curative
treatment; however, the post-operative MST for such
patients is only approximately 12 months. The benefits of
such an aggressive approach have been questioned be-
cause the treatment-related mortality rate is 7.0 percent to
11.5 percent [6-8]. Recently, trimodality therapies such as
combinations of surgical resection and chemoradiotherapy
for operable MPM cases have improved the prognosis
[9-11]. Flores et al. reported a MST of 19 months for
operable MPM [11], and Perrot et al. reported a five-year
overall survival rate of 10 percent following trimodality
treatment. However, the rate of treatment-related mortality
remains high, and is equivalent to approximately 5 percent
of all patients who undergo trimodality treatments [9,10].
Additionally, the rate of treatment-related morbidities
such as atrial arrhythmias, respiratory failure, and pneu-
monia, among others, is 25 percent to 55 percent [9-11].
These complications can reduce a patient’s quality of life.
Moreover, chemotherapy, radiotherapy, or a combi-
nation of both have been considered as palliative therapy
in inoperable cases. Over the past two decades, a num-
ber of single-agent and combination chemotherapy studies
have been performed for MPM. Unfortunately, all the pub-
lished reviews have reported poor response rates of ap-
proximately 30 percent, and a short MST of approximately
10 months [12,13]. In a recent study, Vogelzang et al.
reported that MST for subjects in the pemetrexed/cisplatin
arm was 12.1 months, whereas that for subjects in the cis-
platin monotherapy arm was 9.3 months [14]. However,
this result is still not a satisfactory one.computed tomography images six years after treatment. A chest
(B) were obtained six years after our patient’s completion of
ence of recurrence or metastasis.












Vogelzang [14] Cisplatin (75mg/m2 on day one)/pemetrexed
(500mg/m2 on day one)
Every three weeks,
6.0 courses
226 41 percent 12.1
Nakano [15] Cisplatin (60mg/m2 on day one)/irinotecan
(60mg/m2 on days one, eight, and 15)
Every four weeks,
2.6 courses
15 27 percent 6.5
Tsavaris [16] Cisplatin (100mg/m2 on day one)/vinblastine
(6mg/m2 on days one and eight)
Every four weeks,
4.0 courses
20 25 percent N/A
Ardizzoni [17] Cisplatin (60mg/m2 on day 1)/doxorubicin
(60mg/m2 on day one)
Every three to four weeks, 3.0 to
4.0 courses
26 25 percent 10
Nowak [18] Cisplatin (100mg/m2 on day one)/
gemcitabine
(1000mg/m2 on days one, eight, and 15)
Every four weeks,
4.0 courses
53 33 percent 11.2
Present report Cisplatin (60mg/m2 on day one)/irinotecan
(60mg/m2 on days one, eight, and 15)
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thus underwent systemic chemotherapy with hyperther-
mia. The chemotherapeutic doses of cisplatin 60mg/m2
on day one and irinotecan 60mg/m2 on days one, eight,
and 15, were relatively low compared with the conven-
tional doses (Table 1) [15-18]. Therefore, we speculated
that the remarkable efficacy may have been due to an in-
trinsic effect of hyperthermia or a synergistic effect of the
hyperthermia-chemotherapy combination.
Hyperthermia is known to be directly cytotoxic to can-
cer cells [19-21]. When cells are exposed to elevated
temperatures, damage is inflicted at multiple sites; the
predominant molecular target appears to be proteins
such as heat shock proteins (HSPs) [22]. Roth et al.
reported the effects of heat stress on HSPs [23]. It was
noted that hyperthermia induced the downregulation
heat-stress-induced Hsp40 and Hsp70 expression and
reduced the survival of mesothelioma cells.
Some clinical reports have also reported the benefits
of hyperthermia. Matsuzaki et al. reported on intra-
pleural chemotherapy perfusion with hyperthermia to
induce MPM cell apoptosis. MPM cells obtained from
pleural effusions showed apoptotic action, peaking at
24 hours after perfusion [24]. Xia et al. reported sig-
nificant prolongation of MST by hyperthermia com-
bined with intra-thoracic chemotherapy and radiotherapy
for MPM. Although a complete response was not
achieved, MST was 27.1 months without any severe side
effects [25]. These reports suggest that hyperthermia
may have a special effect on MPM cells, and that the
combination of hyperthermia and chemotherapy may
act synergistically.
Conclusions
This report describes a rare case of a long-term survivor
with MPM. Our patient has been disease-free for morethan seven years without any complications. The com-
bination of hyperthermia and chemotherapy may be a
novel and safe therapeutic option for MPM and can
be considered in cases ineligible for radical treatment.
Further clinical studies of the hyperthermia-chemotherapy
combination are required to confirm its effects on MPM.
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